RecruitingPhase 3NCT07285460
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Intervention
- Fitusiran(drug)
- Enrollment
- 85 target
- Eligibility
- 1-11 years · MALE
- Timeline
- 2025 – 2031
Study locations (18)
- The Luskin Orthopaedic Institute for Children- Site Number : 8400013, Los Angeles, California, United States
- The Center for Inherited Blood Disorders- Site Number : 8400009, Orange, California, United States
- Cure 4 The Kids Foundation- Site Number : 8400001, Las Vegas, Nevada, United States
- Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400008, Hackensack, New Jersey, United States
- Investigational Site Number : 0560002, Brussels, Belgium
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760004, São Paulo, Brazil
- Investigational Site Number : 1240003, Montreal, Quebec, Canada
- Investigational Site Number : 3560002, Mumbai, India
- Investigational Site Number : 3560001, Pune, India
- Investigational Site Number : 3800001, Milan, Milano, Italy
- Investigational Site Number : 6160002, Wroclaw, Lower Silesian Voivodeship, Poland
- Investigational Site Number : 6420001, Iași, Romania
- Investigational Site Number : 6420003, Timișoara, Romania
- Investigational Site Number : 7240001, Esplugues de Llobregat, Barcelona [Barcelona], Spain
- Investigational Site Number : 7240002, Madrid, Spain
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07285460 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)CSL Behring
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPHASE3NCT05662319A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaSanofi